The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...

FDA Approvals and Expansions In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and ...

Moderna’s COVID-19 vaccine will soon have a figurative “made in North Carolina” stamp. Thermo Fisher Scientific, a contract manufacturer of pharmaceuticals, will begin making “hundreds of millions of ...

Northeastern University professors of pharmacy say the updated COVID-19 vaccines available for fall and winter of 2024 are a ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines.

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 trial of V940 (mRNA-4157). V940 is an investigational ...

Studies have shown these vaccines to be effective, with the Pfizer, GSK, and Moderna vaccines preventing ... strains of the RSV virus, called bivalent vaccines, may provide longer protection.